Rezkalla S, Kloner R A, Khatib G, Khatib R
Department of Medicine, Harper Hospital, Detroit, Mich.
Am Heart J. 1990 Dec;120(6 Pt 1):1377-81. doi: 10.1016/0002-8703(90)90251-r.
The effect of captopril on coxsackievirus B3 murine myocarditis was investigated. Thirty-two, 3-week-old mice were infected with coxsackievirus B3 on day 0 of the study, then randomized into a placebo group or a captopril group starting on day 3 of infection. On day 9 of infection, the mice were put to death. Hearts were weighed and processed for light microscopic examination. Heart weight was 125 +/- 19 mg in the control group versus 102 +/- 14 mg in the captopril group (p less than 0.0003). Amount of necrosis as a percentage of left ventricular section was 3.5% (2.0% to 7.5%) in the placebo group versus 2.0% (0.0% to 5.0%) in the captopril group (p less than 0.01). The amount of dystrophic calcification was 5.0% (0.0% to 27.5%) in the placebo group versus 1.3% (0.0% to 20.0%) in the captopril group (p less than 0.01). The extent of the histopathologic involvement by planimetry was 10.2% in the placebo group versus 5.4% in the captopril group (p = 0.052). We conclude that captopril is beneficial in decreasing left ventricular mass and the amount of myocardial necrosis and calcification in the short term in the murine myocarditis model.
研究了卡托普利对柯萨奇病毒B3型小鼠心肌炎的影响。在研究第0天,将32只3周龄小鼠感染柯萨奇病毒B3,然后在感染第3天随机分为安慰剂组或卡托普利组。在感染第9天,处死小鼠。称量心脏重量并进行光镜检查。对照组心脏重量为125±19mg,卡托普利组为102±14mg(p<0.0003)。安慰剂组坏死面积占左心室切片的百分比为3.5%(2.0%至7.5%),卡托普利组为2.0%(0.0%至5.0%)(p<0.01)。营养不良性钙化面积在安慰剂组为5.0%(0.0%至27.5%),卡托普利组为1.3%(0.0%至20.0%)(p<0.01)。通过面积测量法得出的组织病理学累及范围在安慰剂组为10.2%,卡托普利组为5.4%(p = 0.052)。我们得出结论,在小鼠心肌炎模型中,卡托普利在短期内有助于减轻左心室重量以及心肌坏死和钙化的程度。